Jeffrey Gold has been named as CEO of medical device company myoscience.
Gold has previously held the positions of president and chief operating officer at the company. Previously he has held posts as chief executive for Velomedix and CryoVascular Systems as well as being chief operating officer for CardioThoracic Systems.
Concerning his appointment, Gold commented: “I am very excited to assume the responsibility of guiding myoscience through its next development stage. The myoscience tea has built an extremely strong platform technology that targets two distinct markets, aesthetics and peripheral nerve pain.
“We have a strong team of dedicated professionals that will drive myoscience to greater success in the future.”
Prior to his roles at Velomedix, Gold was a venture partner for Longitude Capital where he focused on investments in medical devices.
Rich Ferrari, myoscience executive chairman, added: “Jeff is a seasoned executive with a solid record of success. The myoscience board of directors fully supports the appointment and we are excited to have Jeff accept the leadership role as CEO.”
Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and...